
Henry P Parkman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9529118/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Guideline: Management of Gastroparesis. American Journal of Gastroenterology, 2013, 108, 18-37.	0.4	904
2	American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology, 2004, 127, 1592-1622.	1.3	644
3	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. American Journal of Gastroenterology, 2008, 103, 753-763.	0.4	588
4	Development and Validation of the Rome IV Diagnostic Questionnaire for Adults. Gastroenterology, 2016, 150, 1481-1491.	1.3	400
5	Cellular Changes in Diabetic and Idiopathic Gastroparesis. Gastroenterology, 2011, 140, 1575-1585.e8.	1.3	368
6	Botulinum Toxin A for the Treatment of Delayed Gastric Emptying. American Journal of Gastroenterology, 2008, 103, 416-423.	0.4	318
7	Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology, 1998, 115, 747-762.	1.3	317
8	Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterology and Motility, 2006, 18, 263-283.	3.0	316
9	Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterology and Motility, 2011, 23, 8-23.	3.0	305
10	Investigation of Colonic and Whole-Gut Transit With Wireless Motility Capsule and Radiopaque Markers in Constipation. Clinical Gastroenterology and Hepatology, 2009, 7, 537-544.	4.4	297
11	Consensus Recommendations for Gastric Emptying Scintigraphy: A Joint Report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Journal of Nuclear Medicine Technology, 2008, 36, 44-54.	0.8	295
12	Comparison of gastric emptying of a nondigestible capsule to a radioâ€labelled meal in healthy and gastroparetic subjects. Alimentary Pharmacology and Therapeutics, 2008, 27, 186-196.	3.7	293
13	Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterology and Motility, 2003, 15, 89-102.	3.0	286
14	Clinical Features of Idiopathic Gastroparesis Vary With Sex, Body Mass, Symptom Onset, Delay in Gastric Emptying, and Gastroparesis Severity. Gastroenterology, 2011, 140, 101-115.e10.	1.3	281
15	Gastroparesis-Related Hospitalizations in the United States: Trends, Characteristics, and Outcomes, 1995–2004. American Journal of Gastroenterology, 2008, 103, 313-322.	0.4	267
16	Gastric emptying of a nonâ€digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterology and Motility, 2008, 20, 311-319.	3.0	261
17	Gastroparesis. Nature Reviews Disease Primers, 2018, 4, 41.	30.5	235
18	AGA technical review on nausea and vomiting. Gastroenterology, 2001, 120, 263-286.	1.3	220

#	Article	IF	CITATIONS
19	Characteristics of Patients With Chronic Unexplained Nausea and Vomiting and Normal Gastric Emptying. Clinical Gastroenterology and Hepatology, 2011, 9, 567-576.e4.	4.4	212
20	Wireless Capsule Motility: Comparison of the SmartPill® GI Monitoring System with Scintigraphy for Measuring Whole Gut Transit. Digestive Diseases and Sciences, 2009, 54, 2167-2174.	2.3	202
21	Treatment of Idiopathic Gastroparesis With Injection of Botulinum Toxin Into The Pyloric Sphincter Muscle. American Journal of Gastroenterology, 2002, 97, 1653-1660.	0.4	194
22	American Gastroenterological Association medical position statement: Diagnosis and treatment of gastroparesis. Gastroenterology, 2004, 127, 1589-1591.	1.3	191
23	Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointestinal Endoscopy, 2005, 61, 833-839.	1.0	190
24	Gastric Electrical Stimulation With Enterra Therapy Improves Symptoms From Diabetic Gastroparesis in a Prospective Study. Clinical Gastroenterology and Hepatology, 2010, 8, 947-954.e1.	4.4	186
25	Wireless pHâ€motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterology and Motility, 2010, 22, 874.	3.0	185
26	Effect of gastric acid suppressants on human gastric motility. Gut, 1998, 42, 243-250.	12.1	183
27	Similarities and Differences Between Diabetic and Idiopathic Gastroparesis. Clinical Gastroenterology and Hepatology, 2011, 9, 1056-1064.	4.4	174
28	Cyclic vomiting syndrome in adults. Neurogastroenterology and Motility, 2008, 20, 269-284.	3.0	172
29	Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterology and Motility, 2010, 22, 113-133.	3.0	171
30	Advances in the diagnosis and classification of gastric and intestinal motility disorders. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 291-308.	17.8	168
31	Clinicalâ€histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterology and Motility, 2012, 24, 531.	3.0	164
32	Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Digestive Diseases and Sciences, 2001, 46, 24-29.	2.3	160
33	Whole Gut Transit Scintigraphy in The Clinical Evaluation of Patients With Upper and Lower Gastrointestinal Symptoms. American Journal of Gastroenterology, 2000, 95, 2838-2847.	0.4	152
34	Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis. JAMA - Journal of the American Medical Association, 2013, 310, 2640.	7.4	149
35	Dietary Intake and Nutritional Deficiencies in Patients With Diabetic or Idiopathic Gastroparesis. Gastroenterology, 2011, 141, 486-498.e7.	1.3	148
36	Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. Gastroenterology, 2021, 160, 2006-2017.	1.3	141

#	Article	IF	CITATIONS
37	Clinical and translational advances in esophageal squamous cell carcinoma. Advances in Cancer Research, 2019, 144, 95-135.	5.0	140
38	Comparison of scintigraphy and lactulose breath hydrogen test for assessment of orocecal transit: lactulose accelerates small bowel transit. Digestive Diseases and Sciences, 1997, 42, 10-18.	2.3	126
39	Predictive Factors for Clinical Improvement with Enterra Gastric Electric Stimulation Treatment for Refractory Gastroparesis. Digestive Diseases and Sciences, 2008, 53, 2072-2078.	2.3	126
40	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Alimentary Pharmacology and Therapeutics, 2010, 31, 313-322.	3.7	123
41	Regional Postprandial Differences in pH Within the Stomach and Gastroesophageal Junction. Digestive Diseases and Sciences, 2005, 50, 2276-2285.	2.3	120
42	Assessing pyloric sphincter pathophysiology using Endo <scp>FLIP</scp> in patients with gastroparesis. Neurogastroenterology and Motility, 2015, 27, 524-531.	3.0	120
43	Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology, 2018, 154, 65-76.e11.	1.3	117
44	Electrogastrography and Gastric Emptying Scintigraphy Are Complementary for Assessment of Dyspepsia. Journal of Clinical Gastroenterology, 1997, 24, 214-219.	2.2	112
45	Development and content validity of a gastroparesis cardinal symptom index daily diary. Alimentary Pharmacology and Therapeutics, 2009, 30, 670-680.	3.7	110
46	Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis. Gastroenterology, 2015, 149, 1762-1774.e4.	1.3	110
47	Gastric Per Oral Endoscopic Myotomy (G-POEM) for the Treatment of Refractory Gastroparesis: Early Experience. Digestive Diseases and Sciences, 2018, 63, 2405-2412.	2.3	108
48	Ultrastructural differences between diabetic and idiopathic gastroparesis. Journal of Cellular and Molecular Medicine, 2012, 16, 1573-1581.	3.6	104
49	Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Digestive Diseases and Sciences, 2003, 48, 488-497.	2.3	103
50	Psychological Dysfunction Is Associated With Symptom Severity but Not Disease Etiology or Degree of Gastric Retention in Patients With Gastroparesis. American Journal of Gastroenterology, 2010, 105, 2357-2367.	0.4	103
51	Factors related to abdominal pain in gastroparesis: contrast to patients with predominant nausea and vomiting. Neurogastroenterology and Motility, 2013, 25, 427.	3.0	103
52	Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation. Gastroenterology, 2016, 150, 1292-1304.e2.	1.3	103
53	Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Indexâ€Daily Diary (GCSlâ€DD). Neurogastroenterology and Motility, 2012, 24, 456-463.	3.0	101
54	Abdominal Pain Is a Frequent Symptom of Gastroparesis. Clinical Gastroenterology and Hepatology, 2010, 8, 676-681.	4.4	100

#	Article	IF	CITATIONS
55	Cholinergic effects on human gastric motility. Gut, 1999, 45, 346-354.	12.1	96
56	Gastric Neuromuscular Pathology in Gastroparesis: Analysis of Full-Thickness Antral Biopsies. Digestive Diseases and Sciences, 2010, 55, 359-370.	2.3	96
57	Altered Expression of Ano1 Variants in Human Diabetic Gastroparesis. Journal of Biological Chemistry, 2011, 286, 13393-13403.	3.4	95
58	Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis. Neurogastroenterology and Motility, 2013, 25, 815.	3.0	95
59	Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. Digestive Diseases and Sciences, 2011, 56, 2639-45.	2.3	94
60	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. Neurogastroenterology and Motility, 2010, 22, 527-33, e117.	3.0	91
61	Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. American Journal of Gastroenterology, 1997, 92, 968-75.	0.4	91
62	The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis. Digestive Diseases and Sciences, 2017, 62, 879-893.	2.3	85
63	Gastric Emptying of Solids and Liquids for Evaluation for Gastroparesis. Digestive Diseases and Sciences, 2011, 56, 1138-1146.	2.3	84
64	Association of low numbers of <scp>CD</scp> 206â€positive cells with loss of <scp>ICC</scp> in the gastric body of patients with diabetic gastroparesis. Neurogastroenterology and Motility, 2014, 26, 1275-1284.	3.0	83
65	Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Digestive Diseases and Sciences, 1996, 41, 2025-2031.	2.3	81
66	Simultaneous measurement of gastric emptying with a simple muffin meal using [13C]octanoate breath test and scintigraphy in normal subjects and patients with dyspeptic symptoms. Digestive Diseases and Sciences, 2002, 47, 1657-1663.	2.3	80
67	Gastroduodenal motility and dysmotility: an update on techniques available for evaluation. American Journal of Gastroenterology, 1995, 90, 869-92.	0.4	79
68	Influence of age, gender, and menstrual cycle on the normal electrogastrogram. American Journal of Gastroenterology, 1996, 91, 127-33.	0.4	79
69	Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 1-7.	2.2	78
70	Diabetic and idiopathic gastroparesis is associated with loss of <scp>CD</scp> 206â€positive macrophages in the gastric antrum. Neurogastroenterology and Motility, 2017, 29, e13018.	3.0	77
71	Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study. Clinical Gastroenterology and Hepatology, 2015, 13, 1256-1263.e1.	4.4	75
72	Neurotrophin-3 Improves Functional Constipation. American Journal of Gastroenterology, 2003, 98, 1338-1347.	0.4	74

#	Article	IF	CITATIONS
73	Differential effects of sham feeding and meal ingestion on ghrelin and pancreatic polypeptide levels: evidence for vagal efferent stimulation mediating ghrelin release1. Neurogastroenterology and Motility, 2005, 17, 348-354.	3.0	74
74	High-resolution solid-state manometry of the antropyloroduodenal region. Neurogastroenterology and Motility, 2007, 19, 188-195.	3.0	72
75	Gastric Emptying Scintigraphy. Journal of Clinical Gastroenterology, 2012, 46, 209-215.	2.2	71
76	Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. American Journal of Physiology - Renal Physiology, 2009, 297, G1107-G1114.	3.4	70
77	Regional gastric emptying abnormalities in functional dyspepsia and gastro-oesophageal reflux disease. Neurogastroenterology and Motility, 2006, 18, 894-904.	3.0	68
78	Mirtazapine for symptom control in refractory gastroparesis. Drug Design, Development and Therapy, 2017, Volume11, 1035-1041.	4.3	67
79	Gastric Electric Stimulation for Refractory Gastroparesis: A Prospective Analysis of 151 Patients at a Single Center. Digestive Diseases and Sciences, 2016, 61, 168-175.	2.3	66
80	Optimal evaluation of patients with nonobstructive esophageal dysphagia. Digestive Diseases and Sciences, 1996, 41, 1355-1368.	2.3	65
81	Effect of dietary fat and food consistency on gastroparesis symptoms in patients with gastroparesis. Neurogastroenterology and Motility, 2015, 27, 501-508.	3.0	65
82	Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterology and Motility, 2018, 30, e13196.	3.0	65
83	Symptoms of Gastroparesis: Use of the Gastroparesis Cardinal Symptom Index in Symptomatic Patients Referred for Gastric Emptying Scintigraphy. Digestion, 2008, 78, 144-151.	2.3	64
84	Chronic nausea and vomiting: evaluation and treatment. American Journal of Gastroenterology, 2018, 113, 647-659.	0.4	64
85	Clinical Response and Side Effects of Metoclopramide. Journal of Clinical Gastroenterology, 2012, 46, 494-503.	2.2	61
86	Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. Neurogastroenterology and Motility, 2016, 28, 1902-1914.	3.0	61
87	Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in PatientsÂWith Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1285-1294.e1.	4.4	60
88	Nausea and vomiting in diabetic and idiopathic gastroparesis. Neurogastroenterology and Motility, 2012, 24, 217.	3.0	59
89	Tests of Gastric Neuromuscular Function. Gastroenterology, 2009, 136, 1526-1543.	1.3	57
90	Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. Neurogastroenterology and Motility, 2017, 29, e12981.	3.0	57

Henry P Parkman

#	Article	IF	CITATIONS
91	Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. American Journal of Physiology - Renal Physiology, 2003, 285, G291-G297.	3.4	56
92	Abnormal Ghrelin and Pancreatic Polypeptide Responses in Gastroparesis. Digestive Diseases and Sciences, 2006, 51, 1339-1346.	2.3	54
93	Domperidone Treatment for Gastroparesis: Demographic and Pharmacogenetic Characterization of Clinical Efficacy and Side-Effects. Digestive Diseases and Sciences, 2011, 56, 115-124.	2.3	54
94	Foods Provoking and Alleviating Symptoms in Gastroparesis: Patient Experiences. Digestive Diseases and Sciences, 2015, 60, 1052-1058.	2.3	53
95	Validation of Diagnostic and Performance Characteristics of the Wireless Motility Capsule in Patients With Suspected Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1770-1779.e2.	4.4	53
96	Bloating in Gastroparesis: Severity, Impact, and Associated Factors. American Journal of Gastroenterology, 2011, 106, 1492-1502.	0.4	52
97	Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort. Digestive Diseases and Sciences, 2016, 61, 3545-3551.	2.3	52
98	Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals. Journal of Nuclear Medicine, 2004, 45, 1155-60.	5.0	52
99	Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 <i>>vs</i> > type 2 diabetes. Neurogastroenterology and Motility, 2016, 28, 1001-1015.	3.0	51
100	Multichannel Electrogastrography (EGG) in Normal Subjects: A Multicenter Study. Digestive Diseases and Sciences, 2004, 49, 594-601.	2.3	50
101	Assessment of symptoms during gastric emptying scintigraphy to correlate symptoms to delayed gastric emptying. Neurogastroenterology and Motility, 2010, 22, 539-45.	3.0	50
102	The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0. Journal of Nuclear Medicine, 2013, 54, 2004-2013.	5.0	50
103	Small Intestinal Bacterial Overgrowth in Gastroparesis. Digestive Diseases and Sciences, 2014, 59, 645-652.	2.3	50
104	Idiopathic Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, 59-68.	2.2	49
105	Avoidant/restrictive food intake disorder symptoms are frequent in patients presenting for symptoms of gastroparesis. Neurogastroenterology and Motility, 2020, 32, e13931.	3.0	49
106	Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. Gastroenterology, 2021, 160, 76-87.e4.	1.3	49
107	Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterology and Motility, 2014, 26, 521-528.	3.0	48
108	Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. Journal of Nuclear Medicine, 2018, 59, 691-697.	5.0	48

#	Article	IF	CITATIONS
109	REVIEW: The Use of Botulinum Toxin for the Treatment of Gastrointestinal Motility Disorders. Digestive Diseases and Sciences, 2004, 49, 165-175.	2.3	43
110	Ethnic, Racial, and Sex Differences in Etiology, Symptoms,ÂTreatment, and Symptom Outcomes of Patients With Gastroparesis. Clinical Gastroenterology and Hepatology, 2019, 17, 1489-1499.e8.	4.4	43
111	Chronic intestinal pseudo-obstruction. Current Treatment Options in Gastroenterology, 2005, 8, 3-11.	0.8	42
112	Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. Journal of Neurogastroenterology and Motility, 2016, 22, 650-655.	2.4	42
113	Diagnosis and management of esophageal achalasia. BMJ, The, 2016, 354, i2785.	6.0	42
114	Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. Digestive Diseases and Sciences, 2019, 64, 2242-2255.	2.3	42
115	Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation. American Journal of Physiology - Renal Physiology, 2004, 287, C612-G619.	3.4	41
116	Granisetron Transdermal System Improves Refractory Nausea and Vomiting in Gastroparesis. Digestive Diseases and Sciences, 2014, 59, 1231-1234.	2.3	41
117	Use of a High Caloric Liquid Meal as an Alternative to a Solid Meal for Gastric Emptying Scintigraphy. Digestive Diseases and Sciences, 2013, 58, 2001-2006.	2.3	40
118	Chronic opioids in gastroparesis: Relationship with gastrointestinal symptoms, healthcare utilization and employment. World Journal of Gastroenterology, 2017, 23, 7310-7320.	3.3	40
119	Metoclopramide for the treatment of diabetic gastroparesis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 711-721.	3.0	39
120	Assessment of Gastric Emptying and Small-Bowel Motility: Scintigraphy, Breath Tests, Manometry, and SmartPill. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 49-55.	1.4	38
121	Advanced Training in Neurogastroenterology and Gastrointestinal Motility. Gastroenterology, 2015, 148, 881-885.	1.3	38
122	Characteristics of Nausea and Its Effects on Quality of Life in Diabetic and Idiopathic Gastroparesis. Journal of Clinical Gastroenterology, 2011, 45, 317-321.	2.2	37
123	Autonomic function in gastroparesis and chronic unexplained nausea and vomiting: Relationship with etiology, gastric emptying, and symptom severity. Neurogastroenterology and Motility, 2020, 32, e13810.	3.0	37
124	Differences in intragastric pH in diabetic vs. idiopathic gastroparesis: relation to degree of gastric retention. American Journal of Physiology - Renal Physiology, 2008, 294, G1384-G1391.	3.4	36
125	Effectiveness of gastric electrical stimulation in gastroparesis: Results from a large prospectively collected database of national gastroparesis registries. Neurogastroenterology and Motility, 2019, 31, e13714.	3.0	36
126	Delayed Gastric Emptying Associates With Diabetic Complications in Diabetic Patients With Symptoms of Gastroparesis. American Journal of Gastroenterology, 2019, 114, 1778-1794.	0.4	34

#	Article	IF	CITATIONS
127	Gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in rabbit stomach. American Journal of Physiology - Renal Physiology, 1995, 269, G418-G426.	3.4	33
128	Factors Contributing to Hospitalization for Gastroparesis Exacerbations. Digestive Diseases and Sciences, 2009, 54, 2404-2409.	2.3	33
129	Glucose sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic gastroparesis: An open-label pilot prospective study. PLoS ONE, 2018, 13, e0194759.	2.5	33
130	Migraine and Gastroparesis From a Gastroenterologist's Perspective. Headache, 2013, 53, 4-10.	3.9	32
131	Multichannel Electrogastrography (EGG) in Symptomatic Patients: A Single Center Study. American Journal of Gastroenterology, 2004, 99, 478-485.	0.4	31
132	The Influence of Race on Symptom Severity and Quality of Life in Gastroparesis. Journal of Clinical Gastroenterology, 2013, 47, 757-761.	2.2	31
133	Use of simultaneous high-resolution endoluminal sonography (HRES) and manometry to characterize high pressure zone of distal esophagus. Digestive Diseases and Sciences, 2000, 45, 1660-1666.	2.3	29
134	Achalasia Presenting After Operative and Nonoperative Trauma. Digestive Diseases and Sciences, 2004, 49, 1818-1821.	2.3	28
135	Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous [13C]octanoate breath test and electrogastrography in normal subjects using a muffin meal. Digestive Diseases and Sciences, 2001, 46, 2643-2650.	2.3	26
136	Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. Neurogastroenterology and Motility, 2017, 29, e13068.	3.0	26
137	Reflux Symptoms in Gastroparesis. Journal of Clinical Gastroenterology, 2020, 54, 428-438.	2.2	26
138	Erythromycin inhibits rabbit pyloric smooth muscle through neuronal motilin receptors. Gastroenterology, 1996, 111, 682-690.	1.3	25
139	Variation of symptoms during the menstrual cycle in female patients with gastroparesis. Neurogastroenterology and Motility, 2011, 23, 625-e254.	3.0	25
140	Outcomes of surgical intervention for refractory gastroparesis: a systematic review. Journal of Surgical Research, 2018, 231, 263-269.	1.6	25
141	Gastric electric stimulation for the treatment of gastroparesis. Current Gastroenterology Reports, 2007, 9, 286-294.	2.5	24
142	Identification of Novel Metoclopramide Metabolites in Humans: In Vitro and In Vivo Studies. Drug Metabolism and Disposition, 2010, 38, 1295-1307.	3.3	24
143	Role and safety of fundoplication in esophageal disease and dysmotility syndromes. Journal of Thoracic Disease, 2019, 11, S1610-S1617.	1.4	24
144	Scintigraphy for Evaluation of Patients for GI Motility Disorders—The Referring Physician's Perspective. Seminars in Nuclear Medicine, 2012, 42, 76-78.	4.6	23

#	ARTICLE	IF	CITATIONS
145	Cholecystectomy and Clinical Presentations of Gastroparesis. Digestive Diseases and Sciences, 2013, 58, 1062-1073.	2.3	23
146	Constipation in Patients With Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. Clinical Gastroenterology and Hepatology, 2022, 20, 546-558.e5.	4.4	23
147	Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, doubleâ€blind, randomised, placeboâ€controlled, phase 2 study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1090-1097.	3.7	23
148	Surgical Outcomes After Gastric Electric Stimulator Placement for Refractory Gastroparesis. Journal of Gastrointestinal Surgery, 2013, 17, 620-626.	1.7	22
149	Therapeutic response to domperidone in gastroparesis: AÂprospective study using the <scp>GCSI</scp> â€daily diary. Neurogastroenterology and Motility, 2018, 30, e13246.	3.0	22
150	Effect of Chronic Domperidone Use on QT Interval. Journal of Clinical Gastroenterology, 2019, 53, 648-652.	2.2	22
151	Cannabinoid Use in Patients With Gastroparesis and Related Disorders: Prevalence and Benefit. American Journal of Gastroenterology, 2019, 114, 945-953.	0.4	22
152	Continuous Glucose Monitoring in Gastroparesis. Digestive Diseases and Sciences, 2011, 56, 2646-2655.	2.3	21
153	Drugâ€drug interactions in pharmacologic management of gastroparesis. Neurogastroenterology and Motility, 2015, 27, 1528-1541.	3.0	21
154	Development of a Symptom-Focused Patient-Reported Outcome Measure for Functional Dyspepsia: The Functional Dyspepsia Symptom Diary (FDSD). American Journal of Gastroenterology, 2018, 113, 39-48.	0.4	20
155	Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. Digestive Diseases and Sciences, 2018, 63, 2231-2243.	2.3	20
156	EndoFLIP and Pyloric Dilation for Gastroparesis Symptoms Refractory to Pyloromyotomy/Pyloroplasty. Digestive Diseases and Sciences, 2021, 66, 2682-2690.	2.3	20
157	Treatment of patients with diabetic gastroparesis. Gastroenterology and Hepatology, 2010, 6, 1-16.	0.1	20
158	Enhanced Gastric Emptying Scintigraphy to Assess Fundic Accommodation Using Intragastric Meal Distribution and Antral Contractility. Journal of Nuclear Medicine Technology, 2019, 47, 138-143.	0.8	19
159	Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both?. Journal of Gastrointestinal Surgery, 2020, 24, 2204-2211.	1.7	19
160	Botulinum Toxin A Improves Symptoms of Gastroparesis. Digestive Diseases and Sciences, 2020, 65, 1396-1404.	2.3	18
161	Marijuana Use in Patients with Symptoms of Gastroparesis: Prevalence, Patient Characteristics, and Perceived Benefit. Digestive Diseases and Sciences, 2020, 65, 2311-2320.	2.3	18
162	Gastroparesis in the 2020s: New Treatments, New Paradigms. Current Gastroenterology Reports, 2020, 22, 23.	2.5	18

#	Article	IF	CITATIONS
163	Subtypes of muscarinic receptors regulating gallbladder cholinergic contractions. American Journal of Physiology - Renal Physiology, 1999, 276, G1243-G1250.	3.4	17
164	Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. PLoS ONE, 2017, 12, e0187772.	2.5	17
165	Taste and Smell Disturbances in Patients with Gastroparesis and Gastroesophageal Reflux Disease. Journal of Neurogastroenterology and Motility, 2017, 23, 370-377.	2.4	17
166	CaracterÃsticas del esfÃnter pilórico utilizando EndoFLIP® en gastroparesia. Revista De GastroenterologÃa De México, 2018, 83, 375-384.	0.2	17
167	The impact of gastroparesis on diabetes control: Patient perceptions. Journal of Diabetes and Its Complications, 2016, 30, 826-829.	2.3	16
168	Emerging strategies for the treatment of gastroparesis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 817-825.	3.0	16
169	Utility of Esophageal High-Resolution Manometry in Clinical Practice: First, Do HRM. Digestive Diseases and Sciences, 2018, 63, 3178-3186.	2.3	16
170	Factors that contribute to the impairment of quality of life in gastroparesis. Neurogastroenterology and Motility, 2021, 33, e14087.	3.0	16
171	Methodologic considerations for studies of chronic nausea and vomiting in adults and children. Autonomic Neuroscience: Basic and Clinical, 2017, 202, 28-39.	2.8	15
172	Characterizing Abdominal Pain in Patients With Gastroparesis Into Neuropathic and Nociceptive Components. Journal of Clinical Gastroenterology, 2019, 53, 427-433.	2.2	15
173	Progress in Gastroparesis - A Narrative Review of the Work of the Gastroparesis Clinical Research Consortium. Clinical Gastroenterology and Hepatology, 2022, 20, 2684-2695.e3.	4.4	15
174	Advances in the management of gastroparesis. Current Treatment Options in Gastroenterology, 2007, 10, 283-293.	0.8	14
175	The American neurogastroenterology and motility society gastroparesis cardinal symptom indexâ€daily diary (ANMS GCSlâ€DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis. Neurogastroenterology and Motility, 2019, 31, e13553.	3.0	14
176	Role of Gastric Emptying in Symptoms of Gastroparesis. Gastrointestinal Disorders, 2019, 1, 391-402.	0.8	14
177	Transsphincteric pH Profile at the Gastroesophageal Junction. Clinical Gastroenterology and Hepatology, 2008, 6, 630-634.	4.4	13
178	Effect of Atilmotin, a Motilin Receptor Agonist, on Esophageal, Lower Esophageal Sphincter, and Gastric Pressures. Digestive Diseases and Sciences, 2010, 55, 300-306.	2.3	13
179	Influence of Gastric Emptying and Gut Transit Testing on Clinical Management Decisions in Suspected Gastroparesis. Clinical and Translational Gastroenterology, 2019, 10, e00084.	2.5	13
180	Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium. Clinical Gastroenterology and Hepatology, 2022, 20, e452-e464.	4.4	13

#	Article	IF	CITATIONS
181	The content validity of the ANMS GCSI-DD in patients with idiopathic or diabetic gastroparesis. Journal of Patient-Reported Outcomes, 2018, 2, 61.	1.9	12
182	Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity. Neurogastroenterology and Motility, 2020, 32, e13720.	3.0	12
183	Body weight in patients with idiopathic gastroparesis. Neurogastroenterology and Motility, 2021, 33, e13974.	3.0	12
184	Management of Delayed Gastric Emptying. Clinical Gastroenterology and Hepatology, 2005, 3, 642-646.	4.4	11
185	Training in Gastrointestinal Motility. Digestive Diseases, 2006, 24, 221-227.	1.9	11
186	Fatigue: A Prevalent Symptom in Gastroparesis. Digestive Diseases and Sciences, 2012, 57, 2088-2095.	2.3	11
187	Bodyweight in Patients with Idiopathic Gastroparesis: Roles of Symptoms, Caloric Intake, Physical Activity, and Body Metabolism. Neurogastroenterology and Motility, 2014, 26, 283-289.	3.0	11
188	Endoscopic and Surgical Treatments for Gastroparesis. Gastroenterology Clinics of North America, 2020, 49, 539-556.	2.2	11
189	Dual effects of PACAP on guinea pig gallbladder muscle via PACAP-preferring and VIP/PACAP-preferring receptors. American Journal of Physiology - Renal Physiology, 1997, 272, G1433-G1438.	3.4	10
190	Caregiver Burden in Gastroparesis and GERD: Correlation with Disease Severity, Healthcare Utilization and Work Productivity. Digestive Diseases and Sciences, 2019, 64, 3451-3462.	2.3	10
191	Gastric Electric Stimulation for Refractory Gastroparesis. Journal of Clinical Outcomes Management, 2019, 26, 27-38.	1.7	10
192	Malignancy-induced secondary achalasia. Dysphagia, 1994, 9, 292-6.	1.8	10
193	Diabetes-Related Autoantibodies in Diabetic Gastroparesis. Digestive Diseases and Sciences, 2015, 60, 1733-1737.	2.3	9
194	Effect of Bifidobacterium infantis 35624 (Align) on the Lactulose Breath Test for Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2018, 63, 989-995.	2.3	9
195	Post-Fundoplication Dumping Syndrome: A Frequent "Rare―Complication. ACG Case Reports Journal, 2018, 5, e1.	0.4	9
196	Gastric half emptying time (T ¼) for 4â€h gastric emptying scintigraphy simplifies reporting but reduces detection of gastroparesis. Neurogastroenterology and Motility, 2021, , e14261.	3.0	9
197	Metabolic interactions between prokinetic agents domperidone and erythromycin: anin vitroanalysis. Xenobiotica, 2009, 39, 749-756.	1.1	8
198	376 Enterra® Gastric Electrical Stimulation for Diabetic Gastroparesis: Results from a Multicenter Randomized Study. Gastroenterology, 2009, 136, A-61-A-62.	1.3	8

#	Article	IF	CITATIONS
199	The Gastrointestinal Motility Laboratory. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 171-184.	1.4	8
200	Current advances in treatment of gastroparesis. Expert Opinion on Pharmacotherapy, 2015, 16, 1997-2008.	1.8	8
201	Multiple Rapid Swallows (MRS) Complements Single-Swallow (SS) Analysis for High-Resolution Esophageal Manometry (HREM). Digestive Diseases and Sciences, 2019, 64, 2206-2213.	2.3	8
202	Using gastric emptying scintigraphy to evaluate antral contractions and duodenal bolus propagation. American Journal of Physiology - Renal Physiology, 2020, 318, G203-G209.	3.4	8
203	COVID-19 infection manifesting as a severe gastroparesis flare. Medicine (United States), 2021, 100, e25467.	1.0	8
204	Healthâ€care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3Âyears following the diagnosis of gastroparesis. Neurogastroenterology and Motility, 2022, 34, e14366.	3.0	8
205	Myosin light chain phosphorylation correlates with contractile force in guinea pig gallbladder muscle. Digestive Diseases and Sciences, 2001, 46, 176-181.	2.3	7
206	Islet Cell Associated Autoantibodies and C-Peptide Levels in Patients with Diabetes and Symptoms of Gastroparesis. Frontiers in Endocrinology, 2018, 9, 32.	3.5	7
207	Towards a Fuller Assessment of Gastric Motility in Patients With Upper GI Dyspepsia: Time to Accommodate!. American Journal of Gastroenterology, 2019, 114, 16-18.	0.4	7
208	Factors Associated With Hospital Admissions and Readmissions in Patients With Gastroparesis Using the Nationwide Readmission Database. Journal of Clinical Gastroenterology, 2020, 54, 801-805.	2.2	7
209	Symptom variability throughout the day in patients with gastroparesis. Neurogastroenterology and Motility, 2020, 32, e13740.	3.0	7
210	Which endosurgical treatment for gastroparesis: pyloromyotomy or gastric electrical stimulation?. Endoscopy, 2020, 52, 330-331.	1.8	6
211	Meal Eating Characteristics of Patients with Gastroparesis. Digestive Diseases and Sciences, 2022, 67, 3872-3880.	2.3	6
212	Effect of liquid and solid test meals on symptoms and gastric myoelectrical activity in patients with gastroparesis and functional dyspepsia. Neurogastroenterology and Motility, 2023, 35, e14376.	3.0	6
213	Identification of domperidone metabolites in plasma and urine of gastroparesis patients with LC–ESI-MS/MS. Xenobiotica, 2013, 43, 1073-1083.	1.1	5
214	Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism <i>in vitro</i> . Xenobiotica, 2014, 44, 792-803.	1.1	5
215	143 - Gastric Emptying Changes over Time in Gastroparesis: Comparison of Initial and 48 Week Follow up Gastric Emptying Tests in the Gastroparesis Registry of the Gastroparesis Consortium. Gastroenterology, 2018, 154, S-39.	1.3	5
216	Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis. Clinical Gastroenterology and Hepatology, 2022, 20, e407-e428.	4.4	5

#	Article	IF	CITATIONS
217	Postprandial symptoms in patients with symptoms of gastroparesis: roles of gastric emptying and accommodation. American Journal of Physiology - Renal Physiology, 2022, 323, G44-G59.	3.4	5
218	Persistent Nausea and Abdominal Pain in a Patient With Delayed Gastric Emptying. Clinical Gastroenterology and Hepatology, 2008, 6, 1309-1314.	4.4	4
219	T1345 The Pathological Basis of Gastroparesis. Gastroenterology, 2008, 134, A-536.	1.3	4
220	DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. Journal of Biomedical Informatics, 2012, 45, 316-322.	4.3	4
221	295 Pilot Study of the Safety, Feasibility, and Efficacy of Continuous Glucose Monitoring (CGM) and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG): A Multicenter, Longitudinal Trial by the NIDDK Gastroparesis Clinical Research Consortium (GPCRC). Gastroenterology, 2015, 148, S-64.	1.3	4
222	Su1428 Wireless Motility Capsule Gastric and Extragastric Transit and Pressure Characteristics in a Large Patient Cohort With Gastroparesis Symptoms: Relation to Scintigraphic Findings and Disease Etiology. Gastroenterology, 2015, 148, S-507-S-508.	1.3	4
223	Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches. Handbook of Experimental Pharmacology, 2016, 239, 17-37.	1.8	4
224	Addition of smallâ€bowel transit scintigraphy to gastric emptying for assessment of patients with upper gastrointestinal symptoms. Neurogastroenterology and Motility, 2021, 33, e13987.	3.0	4
225	Epidemiology of Gastroparesis in the United States. Gastroenterology, 2022, 162, 2136-2137.	1.3	4
226	Exploring genetic variability in drug therapy by selecting a minimum subset of the most informative single nucleotide polymorphisms through approximation of a markov blanket in a kernel-induced space. , 2012, , .		3
227	Slow esophageal propagation velocity: association with dysphagia for solids. Neurogastroenterology and Motility, 2013, 25, e44-51.	3.0	3
228	Bolus retention in hiatal hernia identified by highâ€resolution esophageal manometry with impedance. Neurogastroenterology and Motility, 2014, 26, 679-684.	3.0	3
229	Mo1599 Relation of Gastroparesis Symptom Severity to Gastric, Small Bowel, and Colon Transit and Contraction Profiles on Wireless Motility Capsule Testing in a Large Multicenter Cohort. Gastroenterology, 2016, 150, S725.	1.3	3
230	Characterizing the proximal esophageal segment in patients with symptoms of esophageal dysmotility. Neurogastroenterology and Motility, 2020, 32, e13888.	3.0	3
231	Haloperidol Use in the Emergency Department for Gastrointestinal Symptoms: Nausea, Vomiting, and Abdominal Pain. Clinical and Translational Gastroenterology, 2021, 12, e00362.	2.5	3
232	Prevalence and clinical correlates of antinuclear antibody in patients with gastroparesis. Neurogastroenterology and Motility, 2022, 34, e14270.	3.0	3
233	Absorbable antibacterial envelope in the surgical management of Twiddler's syndrome in a patient with gastric electric stimulator: a case report. Digestive Medicine Research, 2020, 3, 76-76.	0.2	3
234	Malignancy-induced secondary achalasia. Dysphagia, 1993, 8, 292-6.	1.8	3

#	Article	IF	CITATIONS
235	Characterizing reflux on high resolution esophageal manometry with impedance. BMC Gastroenterology, 2022, 22, 112.	2.0	3
236	The Gastrointestinal Motility Laboratory. Gastroenterology Clinics of North America, 2007, 36, 515-529.	2.2	2
237	Improving Our Understanding of Gastroparesis. Gastroenterology Clinics of North America, 2015, 44, xv-xvi.	2.2	2
238	Mo1581 Impaired Quality of Life in Gastroparesis: Relationships to Symptoms of Gastroparesis. Gastroenterology, 2016, 150, S718.	1.3	2
239	Gastric Motility. , 2020, , 598-612.		2
240	Vascular pressure bands on high-resolution esophageal manometry with impedance studies. Ecological Management and Restoration, 2020, 33, .	0.4	2
241	Distal Esophageal Impedance Measured by High-resolution Esophageal Manometry With Impedance Suggests the Presence of Barrett's Esophagus. Journal of Neurogastroenterology and Motility, 2020, 26, 344-351.	2.4	2
242	Rheumatologic disorders in patients undergoing esophageal manometry: prevalence, symptom characteristics, and manometric findings. Ecological Management and Restoration, 2021, 34, .	0.4	2
243	Normal Gastrointestinal Tract Physiology. , 2022, , 3-28.		2
244	A cross-sectional study describing peripheral neuropathy in patients with symptoms of gastroparesis: associations with etiology, gastrointestinal symptoms, and gastric emptying. BMC Gastroenterology, 2022, 22, .	2.0	2
245	New advances in the diagnosis and management of nausea and vomiting. The Case Manager, 2002, 13, 83-87.	0.2	1
246	Gastric Emptying Studies. , 2018, , 309-315.		1
247	Modern Approaches for Evaluation and Treatment of Gastrointestinal Motility Disorders. Gastroenterology Clinics of North America, 2020, 49, xv-xvi.	2.2	1
248	Prokinetic agents for gastroparesis. , 2021, , 323-339.		1
249	Detection and characteristics of rumination syndrome in patients presenting for gastric symptom evaluation. Neurogastroenterology and Motility, 2021, 33, e14103.	3.0	1
250	Impact of patient position on esophageal motility disorders using high-resolution esophageal manometry with impedance (HREMI): supine versus upright swallows. Esophagus, 2021, 18, 880-888.	1.9	1
251	Gastroparesis. , 2020, , 720-730.		1
252	Gastric Emptying Scintigraphy Results in the ROME III Subgroup Classifications for Functional Gastroduodenal Disorders. American Journal of Gastroenterology, 2007, 102, S507.	0.4	1

Henry P Parkman

#	Article	IF	CITATIONS
253	Abdominal pain in gastroparesis. , 2022, , 173-188.		1
254	S0351 Characterizing Reflux on High Resolution Esophageal Manometry With Impedance. American Journal of Gastroenterology, 2020, 115, S173-S173.	0.4	1
255	Hiatal hernias associated with acid reflux: size larger than 2Âcm matters. Ecological Management and Restoration, 2022, , .	0.4	1
256	Nonulcer dyspepsia. Current Treatment Options in Gastroenterology, 1998, 1, 15-19.	0.8	0
257	Disorders of gastric emptying. , 0, , 903-935.		0
258	Gastroparesis. Frontiers of Gastrointestinal Research, 2014, , 25-37.	0.1	0
259	Gastroparesis, Postprandial Distress. , 2018, , 269-281.		0
260	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 999-1000.	4.4	0
261	Gastroparesis. , 2020, , 265-280.		0
262	Evaluating response in gastroparesis: Patient reported outcome measures and survey instruments. , 2021, , 451-460.		0
263	Studies from the NIH Gastroparesis Clinical Research Consortium: Towards improving our understanding and treatment of gastroparesis. , 2021, , 443-449.		0
264	Abdominal pain in gastroparesis: Prevalence, potential causes and management. , 2021, , 361-375.		0
265	Gastric emptying scintigraphy. , 2021, , 125-142.		0
266	Editorial: on the road towards treatment of gastroparesis—accelerating, but do we get closer? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 185-186.	3.7	0
267	Pain Management for Gastroparesis. , 2012, , 289-302.		0
268	Minimally Invasive Fundoplication is Safe and Effective in Patients with Severe Esophageal Hypomotility. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2016, 11, 396-399.	0.9	0
269	Future Directions in Understanding Nausea and Vomiting. , 2017, , 211-217.		0